Biogen (BIIB) Long-Term Deferred Tax (2017 - 2026)

Biogen has reported Long-Term Deferred Tax for 10 years, with the latest figure at $202.1 million in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax fell 38.92% year-over-year to $202.1 million in Q2 2026; TTM through Jun 2026 was $202.1 million, a 38.92% decrease from a year earlier, with the FY2025 full-year figure at $292.5 million, down 9.78% from the prior year.
• Long-Term Deferred Tax was $202.1 million for Q2 2026 at Biogen, down from $238.2 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $1.3 billion in Q1 2022, with the low at $202.1 million in Q2 2026.
• Average Long-Term Deferred Tax over 5 years is $785.2 million, with a median of $921.8 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Long-Term Deferred Tax gained 0.19% in 2022, then slumped 67.75% in 2025.
• Over 5 years, Long-Term Deferred Tax stood at $1.2 billion in 2022, then decreased by 24.28% to $928.6 million in 2023, then sank by 65.09% to $324.2 million in 2024, then fell by 9.78% to $292.5 million in 2025, then slumped by 30.91% to $202.1 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $202.1 million (Q2 2026), $238.2 million (Q1 2026), and $292.5 million (Q4 2025), per Business Quant data.